Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Multiple Acquisitions Expected In Next 12 Months - CEO Gibbons

This article was originally published in The Tan Sheet

Executive Summary

Perrigo is eyeing possible near-term acquisition candidates in three main areas - global operations, nutritionals and new delivery vehicles - as the private labeler comes closer to putting its recent operational woes behind it.

You may also be interested in...



NBTY Resistance To Numico Dominance Cited By Analysts; Stock Rises 79%

NBTY's vertical integration, international presence and acquisition history positions the supplement supplier/retailer as the leading challenger to Royal Numico, gaining the admiration of investors in the first quarter of 2001.

Perrigo New Product Program, Quality Control Back On Track In FY 2002

Corrective actions taken in response to an unfavorable FDA inspection of Perrigo's Allegan, Mich. facility will preclude the planned November launch of minoxidil 5% and stall the company's pipeline, Perrigo told analysts in an Oct. 25 conference call.

Perrigo Extended-Release Acetaminophen Launch Delayed By QC Issues

Perrigo has postponed its plans to market private label extended-release acetaminophen until it can resolve quality control issues outlined in a recent FDA warning letter.

Related Content

Topics

UsernamePublicRestriction

Register

PS092407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel